Nancy Thornberry

October 9, 2026

Denali Therapeutics Shares Test Fair Value Amid Pullback. Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.

October 15, 2026

Schrödinger (SDGR) Announces New Battery Research, Analyst Targets Rise. Schrödinger’s research team published a study in Nature that provides new insights into lithium‑ion battery chemistry, showcasing the company’s computational chemistry capabilities. Analyst houses TD Cowen and BMO Capital each lifted their price targets, citing the potential impact of the battery work and broader AI applications. At the same time, other analysts expressed mixed views on the company’s AI growth, resulting in a modest upward adjustment to its fair‑value estimate.

October 17, 2026

Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.